Related Experiment Video
Updated: Jul 28, 2026

08:24
Isolation and Culture of Primary Endothelial Cells from Canine Arteries and Veins
Published on: November 18, 2016
Increased atrial natriuretic factor secretion after endothelin injection in dogs
H Tsuchiya1, A Otsuka, H Mikami
1Department of Geriatric Medicine, Osaka University Medical School, Japan.
Summary
Synthetic porcine endothelin (pET) significantly increased mean blood pressure and right atrial pressure in dogs. This hemodynamic change, caused by pET, also induced atrial natriuretic factor (ANF) release.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
Background:
- Endothelin is a potent vasoconstrictor peptide.
- Atrial natriuretic factor (ANF) plays a role in regulating blood pressure and fluid balance.
Purpose of the Study:
- To investigate the hemodynamic and hormonal effects of synthetic porcine endothelin (pET) in anesthetized dogs.
- To determine if pET administration influences atrial natriuretic factor (ANF) release.
Main Methods:
- Anesthetized dogs received intravenous bolus injections of pET at doses of 40 pmol/kg and 400 pmol/kg.
- Mean blood pressure (MBP), right atrial pressure (RAP), and plasma ANF concentrations were monitored.
- Correlation analysis was performed between changes in RAP and ANF.
Main Results:
- A low dose of pET (40 pmol/kg) did not significantly alter MBP, RAP, or ANF.
- A high dose of pET (400 pmol/kg) significantly increased MBP, RAP, and ANF.
- A strong positive correlation was observed between the increase in RAP and the increase in ANF.
Conclusions:
- Exogenously administered pET in anesthetized dogs alters hemodynamics, causing significant increases in MBP and RAP.
- pET administration induces ANF release, suggesting a link between elevated RAP and ANF secretion.
- The findings support the hypothesis that increased RAP is a stimulus for ANF release.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

